Piper Sandler raised the firm’s price target on RxSight (RXST) to $11 from $10 and keeps a Neutral rating on the shares. The firm is updating a handful of its models to adjust for preliminary Q4 results and initial full year 2026 guidance announcements from this past week or so.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST: